AAN 2024 | Establishing the North American Prodromal Synucleinopathy (NAPS) Consortium

 
 
 

Aleksandar Videnovic, MD, Massachusetts General Hospital, Harvard Medical School, Boston, MA, talks on the establishment of the North American Prodromal Synucleinopathy (NAPS) consortium. The goals of the consortium are two-fold: to recruit patients with REM sleep behavior disorder (RBD) for a longitudinal natural history study centered on biomarker discovery and to develop a cohort-ready population who can be enrolled in disease modifying therapy trials when they launch. This interview took place at the American Academy of Neurology (AAN) Annual Meeting 2024 in Denver, CO.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

 
Previous
Previous

Why Acting Out in Dreams May Signal a Health Issue

Next
Next

What is Frontotemporal Dementia?